Table 1.

Evolutionarily Conserved Segments Downstream of H19 and the Summary of Transgenesis Experiments

Segment	Position	Size (bp)	Sequence identity (%)	No. of embryo		Major sites of expression	Tissue-specific enhancer activity
Segment	Position	Size (bp)	Sequence identity (%)	with integration	with expression	Major sites of expression	Tissue-specific enhancer activity
CS1	10344–10571	228	78	15	5	ganglionic placode of cranial nerves	+
CS2	11605–12076	472	78	9	5	various	−
CS3	12846–13089	244	72	9	4 (+1)	sclerotome	+
CS4	14280–14664	385	68	16	2 (+3)	liver, gut	+
CS5	18151–18535	385	70	4	3	ectoderm of limb buds, neural tube floor plate	+
CS6	21142–21501	360	68	6	5	myotome, rib primordia, intercostal muscles	+
CS7	23733–23963	231	74	10	7	mesenchymal condensation of limb buds	+
CS8	24834–25111	278	85	11	4	various	−
CS9	32288–32773	486	71	8	6	myotome, rib primordia, intercostal muscles	+
CS10	35463–35748	286	79	9	0	—	−

↵Nucleotide position and segment size are given according to the mouse sequence (GenBank accession no. AF049091).
↵Nucleotide sequence identity between the human and mouse sequences is shown.
↵Number of embryos that showed ectopic expression only is indicated in parentheses.

Comparative Genomic Sequencing Identifies Novel Tissue-Specific Enhancers and Sequence Elements for Methylation-Sensitive Factors Implicated in Igf2/H19 Imprinting